Trevi Therapeutics
IPOPassionate about Progress
Public · New Haven, United States · Founded 2011 · $50.5M raised
- Headquarters
- New Haven, Connecticut
- Employees
- 11–50
- Founded
- 2011
- Website
- trevitherapeutics.com
- Total Funding
- $50.5M
- Last Round
- $50.5M Series CAug 2017
- Rounds
- 1
- Type
- Public
About
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) to help patients suffering from chronic cough by targeting the central and peripheral cough reflex arc. The company has released positive Phase 2b results from its CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF) and its Phase 2a RIVER trial for refractory chronic cough (RCC), and is now advancing toward Phase 3 trials. Founded in 2011 and headquartered in New Haven, Connecticut, Trevi is listed on NASDAQ under the ticker TRVI.
Summary
Trevi Therapeutics is a Healthcare company based in New Haven, United States, founded in 2011. It has raised $50.5M in total across 1 round, most recently a $50.5M Series C round in Aug 2017. Investors include New Enterprise Associates.
Funding History
Aug 2017
Investors
Similar Companies
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
China's leading blood products manufacturer
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/trevi-therapeutics"><img src="https://indexed.vc/api/badge/company/trevi-therapeutics" alt="Trevi Therapeutics on Indexed.vc" width="260" height="76" /></a>